Cohance Lifesciences Ltd. NSE: COHANCE | BSE: 543064

Cohance Lifesciences Live Share Price Today, Share Analysis and Chart

Name: Cohance Lifesciences Ltd.: Is Infosys Ltd. worth buying?
Item: Cohance Lifesciences Ltd.
Rating: 1.705958375
Author: Trendlyne DVM scores

Expensive Underperformer

about

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

527.50 -4.90 (-0.92%)

Near 52W Low of ₹518.15

818.6K

NSE+BSE Volume

NSE 30 Dec, 2025 3:31 PM (IST)

Loading... You have run out of DVM views!

Subscribe now to see details

Medium Financial Strength

- / 100

Expensive Valuation

- / 100

Technically Bearish

31.3 / 100

Expensive Underperformer These stocks have average quality, expensive valuations and weak momentum. Investors should exercise caution View Similar Embed DVM

801

1Yr Price target upside is 52%

9 analysts

Cohance Lifesciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

35 Votes:

Buy 68.57%

Sell 17.14%

Hold 14.29%

Cohance Lifesciences Live Share Price Today, Share Analysis and Chart

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

Near 52W Low of ₹518.15

SWOT Analysis

Cohance Lifesciences Live Price Chart